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Clinical Trial
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Dry eye disease (DED) after cataract surgery has become a critical concern, and various therapeutic 
options have been developed. Recently, preservative-free diquafosol ophthalmic solution has been 
introduced; however, its therapeutic effect on DED after cataract surgery has not been reported. 
We investigated the efficacy of preservative-free diquafosol in patients with pre-existing DED after 
cataract surgery. We divided subjects who were diagnosed with DED and scheduled to undergo cataract 
surgery, into 3 groups (preservative-free diquafosol, group 1; preservative-containing diquafosol, 
group 2; preservative-free hyaluronate, group 3), and each eye drops was administered 6 times daily 
after surgery. Tear break up time (TBUT), Ocular Surface Disease Index (OSDI), corneal staining score, 
lid margin abnormality, and meibum quality improved over time in group 1. Groups 1 and 2 had 
significantly superior TBUT, meibomian gland dysfunction grade, and meibomian gland expressibility 
throughout the study period than group 3. Meibum quality of group 1 was significantly better than 
group 2 at 1 and 3 months after surgery. Preservative-free diquafosol showed better efficacy in treating 
DED after cataract surgery than preservative-containing diquafosol or preservative-free hyaluronate. 
Preservative-free diquafosol may serve as a reliable option for the management of patients with pre-
existing DED after phacoemulsification.
Today, cataract surgery has become one of the safest and most effective ocular surgical procedures owing to 
improvements in surgical techniques and instruments. However, a significant number of patients who undergo 
cataract surgery suffer postoperative discomfort and irritation, pain, dryness, burning sensation, and foreign 
body sensations1–3. Potential cause(s) of dry eye disease (DED) after cataract surgery include microscope-induced 
thermal and light toxicity, mechanical damage to the corneal tissue, irrigation of the ocular surface, chemical 
sterilization of the conjunctival sac and eyelid, transection of the corneal nerves by corneal incision, topical anaes-
thetic use, and use of topical eye drops containing preservatives4–6. Moreover, several recent studies have reported 
that a common cause of postoperative discomfort in these patients is pre-existing DED6,7. The deformed ocular 
surface due to DED after surgery affects optical quality considerably, resulting in decreased patient satisfaction 
with vision quality. In the era of improved surgical outcomes and extremely elevated patient expectations due to a 
proven high level of surgical accuracy, DED related postoperative discomfort is unacceptable anymore.
Many options to treat DED after cataract surgery have been developed8. Artificial tears are commonly used 
as a first line management strategy for postoperative DED, with several studies revealing their effectiveness at 
reducing DED signs and symptoms9,10. The postoperative use of cyclosporine 0.05% topical eye drops has led to 
improvement in dry eye symptoms and visual quality following cataract surgery11,12. Recently, diquafosol sodium 
ophthalmic solution has also been used for the management of DED after cataract surgery2,5,6,13. Diquafosol is 
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a dinucleotide derivative and functions as an agonist of the purinergic P2Y2 receptor14. Diquafosol is known to 
stimulate not only mucin secretion from goblet cells but also water secretion from conjunctival epithelial cells and 
the accessory lacrimal glands14,15. Studies have shown that diquafosol is very effective in treating and alleviating 
symptoms of DED after cataract surgery2,5,6,13. Furthermore, several studies have shown that topical diquafosol is 
more effective for managing DED after cataract surgery than artificial tears5,6. Preservative-free diquafosol oph-
thalmic solution has been introduced recently. The use of other eye drops without preservatives has been shown 
to play an important role in the treatment of DED after cataract surgery with reduced adverse reactions16. At pres-
ent, however, there is no study that has evaluated the therapeutic effect of preservative-free diquafosol ophthalmic 
solution on DED after cataract surgery. Therefore, in this study, we compared the efficacy of preservative-free 
diquafosol ophthalmic solution with that of preservative-containing diquafosol and preservative-free sodium 
hyaluronate ophthalmic solutions, which are widely used in patients with DED after cataract surgery.
Results
This study included 38 eyes in group 1, 41 eyes in group 2, and 38 eyes in group 3. Table 1 presents the base-
line characteristics of the 3 groups of patients. There were no significant differences in laterality, age, or sex 
among the 3 groups (Table 1). There were no significant differences in preoperative tear break up time (TBUT) 
(4.6 ± 2.2, 5.0 ± 2.5, and 4.6 ± 1.8 s for groups 1, 2, and 3, respectively) or Ocular Surface Disease Index (OSDI) 
(22.10 ± 12.93, 23.49 ± 11.38, and 22.30 ± 9.01 for groups 1, 2, and 3, respectively) among the 3 groups. In addi-
tion, no significant differences were observed in preoperative corneal staining scores, Schirmer test scores, or 
meibomian gland dysfunction (MGD) parameters among the 3 groups (Table 1). There was no significant differ-
ence in operation time among the 3 groups (P = 0.097).
Dry eye parameters. The preoperative and postoperative dry eye parameters for the 3 groups are summa-
rized in Table 2. The TBUT for groups 1 and 2 showed significant improvement from the preoperative values and 
were significantly longer than that of group 3 at 1 month postoperatively. However, at 3 months after surgery, only 
group 1 evidenced significant improvements from the preoperative values and had significantly longer TBUT 
than that of group 3. We also found significant improvements in in TBUT in groups 1 and 2 when compared to 
group 3 in the overall difference analysis (P < 0.001; Fig. 1a).
OSDI scores were significantly reduced in groups 1 and 2 after surgery across all study periods. There were sig-
nificant differences between groups 1 and 3 and between groups 2 and 3 in OSDI scores at 1 month after surgery. 
At 3 months postoperatively, OSDI scores for group 3 were significantly reduced below the preoperative value. 
Given this, there was no significant difference noted between groups 2 and 3. However, at 3 months after surgery, 
the reduction in OSDI scores of group 1 was higher than that of the other 2 groups and a significant difference in 
OSDI scores between groups 1 and 3 persisted. In the overall difference analysis, a significant difference was also 
observed between groups 1 and 3 (Fig. 1d; P = 0.021).
Corneal staining scores for all groups were significantly better than the preoperative values across all study 
periods; however, there were no significant differences among the 3 groups. Schirmer test results remained 
unchanged from the preoperative values and there were no differences among the 3 groups during the entire 
Group 1 (38 eyes) Group 2 (41 eyes) Group 3 (38 eyes) P-value
Age (y) 67.7 ± 8.3 71.6 ± 9.4 68.0 ± 7.6 0.058
Sex
  Male 13 17 12
0.694
  Female 25 24 26
Eyes
  OD 22 20 19
0.715
  OS 16 21 19
TBUT (s) 4.6 ± 2.2 5.0 ± 2.5 4.6 ± 1.8 0.925
Schirmer test (mm) 15.5 ± 8.6 13.1 ± 8.7 11.5 ± 7.6 0.076
Corneal staining score 0.66 ± 1.07 0.63 ± 0.89 0.84 ± 0.59 0.051
OSDI 22.10 ± 12.94 23.49 ± 11.38 22.30 ± 9.01 0.836
LLT (nm) 80.82 ± 18.77 86.00 ± 19.17 82.25 ± 20.10 0.484
MGD stage 2.61 ± 1.11 2.44 ± 1.18 2.34 ± 1.10 0.407
Lid margin abnormality 2.58 ± 1.00 2.34 ± 1.37 2.03 ± 1.20 0.174
Meibomian gland 
expressibility 1.84 ± 1.05 1.88 ± 1.01 1.61 ± 0.95 0.327
Meibum quality 12.18 ± 5.92 10.22 ± 5.73 10.16 ± 6.77 0.152
Meibomian gland dropout 1.11 ± 0.73 1.37 ± 1.07 1.47 ± 1.13 0.467
Table 1. Demographic and Other Baseline Characteristics for Each Group of Patients with Dry Eye Before 
Cataract Surgery. Data are presented as mean ± standard deviation. TBUT = tear breakup time; OSDI = Ocular 
Surface Disease Index; LLT = lipid layer thickness; MGD = meibomian gland dysfunction. P-value indicates the 
statistical analysis among the three groups.
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study period. There were no significant overall differences among the 3 groups with respect to corneal staining 
scores or Schirmer test scores.
Meibomian gland dysfunction parameters. The parameters for MGD are summarized in Table 2. At 1 
month after surgery, the MGD stage was significantly reduced in group 2 from that before surgery, although there 
was no significant difference among the 3 groups. However, at 3 months postoperatively, only group 1 showed 
significant improvement from the preoperative value, with significantly better MGD stage results than group 3. 
In the overall difference analysis, MGD stage was significantly better in group 1 and group 2 when compared with 
group 3 (Fig. 1; P < 0.001).
At 3 months after surgery, meibomian gland expressibility of groups 1 and 2 significantly improved from the 
preoperative condition and showed significant differences when compared with group 3. Similarly, there were 
Group 1 (38 eyes) Group 2 (41 eyes) Group 3 (38 eyes) P-value
TBUT (sec)
  Preoperative 4.6 ± 2.2 5.0 ± 2.5 4.6 ± 1.8 0.925
  4wks 6.3 ± 3.6* 7.0 ± 2.8* 3.7 ± 1.4‡§ <0.001
  12wks 6.5 ± 3.5* 5.0 ± 2.8 4.7 ± 2.3‡ 0.038
Schirmer test (mm)
  Preoperative 15.5 ± 8.6 13.1 ± 8.7 11.5 ± 7.6 0.076
  4wks 13.7 ± 8.9 11.4 ± 8.0 10.6 ± 6.1 0.389
  12wks 12.2 ± 9.0 13.2 ± 9.3 14.2 ± 8.6 0.396
Corneal staining score
  Preoperative 0.66 ± 1.07 0.63 ± 0.89 0.84 ± 0.59 0.051
  4wks 0.24 ± 0.60* 0.29 ± 0.51* 0.29 ± 0.52* 0.693
  12wks 0.23 ± 0.43* 0.43 ± 0.57* 0.26 ± 0.45* 0.263
OSDI
  Preoperative 22.10 ± 12.94 23.49 ± 11.38 22.30 ± 9.01 0.836
  4wks 14.99 ± 10.42* 15.00 ± 9.19* 21.29 ± 12.57‡§ 0.015
  12wks 10.35 ± 10.55* 15.43 ± 12.24* 17.63 ± 11.45*‡ 0.037
LLT (nm)
  Preoperative 80.82 ± 18.77 86.00 ± 19.17 82.25 ± 20.10 0.484
  4wks 76.24 ± 21.32 84.70 ± 21.66 86.03 ± 18.15 0.070
  12wks 83.29 ± 19.91 85.23 ± 22.70 84.55 ± 22.12 0.749
MGD stage
  Preoperative 2.61 ± 1.11 2.44 ± 1.18 2.34 ± 1.10 0.407
  4wks 2.27 ± 1.07* 1.90 ± 1.39* 2.58 ± 1.13 0.071
  12wks 1.71 ± 1.19* 2.13 ± 1.07 2.68 ± 1.07‡ 0.003
Lid margin abnormality
  Preoperative 2.58 ± 1.00 2.34 ± 1.37 2.03 ± 1.20 0.174
  4wks 2.08 ± 1.06* 1.80 ± 1.19* 2.21 ± 1.26 0.246
  12wks 1.71 ± 1.10* 2.13 ± 1.17 2.06 ± 1.04 0.285
Meibomian gland expressibility
  Preoperative 1.84 ± 1.05 1.88 ± 1.01 1.61 ± 0.95 0.327
  4wks 1.41 ± 0.83 1.02 ± 0.99* 1.55 ± 0.98§ 0.043
  12wks 1.00 ± 0.89* 1.33 ± 0.84* 1.88 ± 0.88‡§ <0.001
Meibum quality
  Preoperative 12.18 ± 5.92 10.22 ± 5.73 10.16 ± 6.77 0.327
  4wks 10.14 ± 3.74* 8.05 ± 6.29*† 11.05 ± 4.75§ 0.007
  12wks 6.55 ± 4.15* 9.86 ± 4.54† 12.94 ± 6.02*‡§ <0.001
Meibomian gland dropout
  Preoperative 1.11 ± 0.73 1.37 ± 1.07 1.47 ± 1.13 0.467
  4wks 1.09 ± 0.75 1.34 ± 0.99 1.42 ± 1.18 0.547
  12wks 1.06 ± 0.74 1.44 ± 1.01 1.50 ± 1.16 0.234
Table 2. Changes in Dry Eye Parameters and Meibomian Gland Dysfunction Parameters between Preoperative 
and 4 and 12 Weeks After Cataract Surgery. Data are presented as means ± standard deviation. TBUT = tear 
breakup time; OSDI = Ocular Surface Disease Index; LLT = lipid layer thickness; MGD = meibomian gland 
dysfunction. P-value indicates the statistical analysis among the three groups. *Indicates a statistically significant 
compared with preoperative value; †indicates a statistically significant difference between groups A and B in 
post hoc analysis; ‡indicates a statistically significant difference between groups A and C in post hoc analysis; 
§indicates a statistically significant difference between groups B and C in post hoc analysis.
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significant differences between groups 1 and 3 and between groups 2 and 3, as revealed by overall difference 
analyses (Fig. 1; P < 0.001). The grade of lid margin abnormality and meibum quality in groups 1 and 2 were 
significantly improved from the preoperative conditions at 1 month postoperatively; however, only group 1 expe-
rienced significant improvements at 3 months after surgery. Although there were no significant differences among 
the 3 groups in lid margin abnormality, overall difference analysis showed significant improvement in lid margin 
abnormality of group 1 when compared with group 3. Meibum quality of group 1 demonstrated statistically sig-
nificant improvements when compared with group 2 or group 3 in overall difference analysis (Fig. 1; P < 0.001). 
The lipid layer thickness (LLT) was unchanged after surgery, and there were no differences noted among the 3 
groups across the entire study period.
Figure 1. Dry eye changes and meibomian gland dysfunction (MGD) parameters during the treatment period 
in patients with pre-existing dry eye disease (DED). Mean changes in tear breakup time (TBUT) (a), Schirmer 
test scores (b), corneal staining scores (c), and Ocular Surface Disease Index (OSDI) (d) were used to assess dry 
eye parameters. Mean changes in lipid layer thickness (LLT) (e), MGD stage (f), lid margin abnormalities (g), 
meibomian gland expressibility (h), and meibum quality (i) were used as MGD parameters. Data are presented 
as mean values ± standard error of the mean (SEM). P-values are presented next to all graphs for each study 
period, indicating the results of statistical analyses among the 3 groups for that period using analysis of variance; 
¶P-value indicates the overall difference analysis throughout the study period by generalized estimating 
equation; †indicates a statistically significant difference between groups 1 and 2 per post hoc analysis; ‡indicates 
a statistically significant difference between groups 1 and 3 per post hoc analysis; §indicates a statistically 
significant difference between groups 2 and 3 per post hoc analysis.
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Higher-order aberrations. Preoperative and postoperative higher-order aberrations (HOAs) for the 3 
groups are summarized in Table 3. Values for HOAs including total HOAs, spherical aberrations, coma, trefoil, 
and secondary astigmatism, for all 3 groups were significantly decreased below the preoperative values in all study 
periods, and there were no significant differences among the 3 groups. Furthermore, no significant differences 
were noted among the 3 groups in the overall difference analysis throughout the study period (Fig. 2).
Discussion
The present study investigated the clinical efficacy of preservative-free diquafosol 3% ophthalmic solution compared 
with preservative-containing diquafosol 3% ophthalmic solution and preservative-free sodium hyaluronate 0.15% 
ophthalmic solution in pre-existing DED patients who underwent cataract surgery. As reported previously5,6,10, 
diquafosol and hyaluronate treatment improved dry eye symptoms and HOAs in this study. Although corneal 
HOAs were comparable among the 3 groups, dry eye symptoms were much improved in the diquafosol treatment 
groups as compared to the hyaluronate treatment group. In addition, though dry-eye and MGD parameters were 
comparable between the preservative-free and preservative-containing diquafosol groups at 1 month postopera-
tively, these improvements were most robust in the preservative-free diquafosol group at 3 months after surgery.
According to a meta-analysis of randomized controlled trials comparing the efficacy of diquafosol and artifi-
cial tears for the management of DED following phacoemulsification6, diquafosol significantly improved multiple 
outcomes including TBUT, Schirmer test scores, and corneal fluorescein staining scores beyond those obtained 
from the use of artificial tears. Similarly, Park and colleagues revealed that OSDI was significantly improved in 
diquafosol-treated individuals5.
We found that TBUT was better in diquafosol groups than in hyaluronate group at 1 month after surgery, 
which implies that diquafosol is more effective than hyaluronic acid in dry eye treatment after cataract surgery, as 
suggested by the previous studies. Similarly, the postoperative OSDI was better in diquafosol groups than in hya-
luronate group. Although the TBUT and OSDI results of the present study were similar to those reported previ-
ously, there were no significant differences in the Schirmer test or corneal staining scores among the 3 groups. Wu 
and colleagues reported that unlike TBUT, Schirmer test scores which evaluate aqueous tear production, did not 
demonstrate consistent improvements after diquafosol treatment in DED patients17, as we also report in the cur-
rent study. Other studies have also shown that Schirmer test scores did not improve after diquafosol treatment of 
DED patients following cataract surgery2,13. Given the similarity of results between our study and previous studies, 
we contend that increased mucin secretion with diquafosol treatment plays an important role in tear film stability 
over aqueous secretion. Notably, corneal staining scores were improved in all the 3 groups, with no significant dif-
ferences among the 3 groups. Several previous studies have also demonstrated no significant differences in corneal 
staining scores between diquafosol and artificial tear groups in patients with DED after phacoemulsification5,18,19.
Although, few studies have investigated the efficacy of diquafosol for MGD20–22, diquafosol has been shown 
to have beneficial effects on the condition. Some potential mechanisms for this have been explored. P2Y2 recep-
tors have been found in the meibomian gland23, and previous studies have suggested that P2Y2 agonists increase 
the concentration of intracellular lipids in cultured rabbit meibomian gland cells and in Cu, Zn-superoxide 
dismutase-1 knockout mice24,25. Until now, there have been no studies evaluating the efficacy of diquafosol in 
Group 1 (38 eyes) Group 2 (41 eyes) Group 3 (38 eyes) P-value
Total Higher order aberrations
  Preoperative 0.54 ± 0.27 0.50 ± 0.26 0.56 ± 0.25 0.538
  4wks 0.22 ± 0.14* 0.28 ± 0.20* 0.28 ± 0.18* 0.214
  12wks 0.28 ± 0.15* 0.31 ± 0.25* 0.30 ± 0.13* 0.590
Spherical Aberration
  Preoperative 0.29 ± 0.17 0.25 ± 0.14 0.32 ± 0.19 0.180
  4wks 0.08 ± 0.58* 0.11 ± 0.08* 0.12 ± 0.11* 0.370
  12wks 0.13 ± 0.08* 0.12 ± 0.10* 0.15 ± 0.10* 0.117
Coma
  Preoperative 0.25 ± 0.13 0.24 ± 0.16 0.27 ± 0.14 0.564
  4wks 0.11 ± 0.08* 0.14 ± 0.13* 0.12 ± 0.09* 0.474
  12wks 0.12 ± 0.09* 0.16 ± 0.19* 0.14 ± 0.08* 0.281
Trefoil
  Preoperative 0.27 ± 0.21 0.26 ± 0.18 0.25 ± 0.15 0.969
  4wks 0.13 ± 0.10* 0.17 ± 0.14* 0.17 ± 0.14* 0.245
  12wks 0.18 ± 0.12* 0.18 ± 0.13* 0.16 ± 0.10* 0.774
Secondary astigmatism
  Preoperative 0.10 ± 0.08 0.08 ± 0.06 0.08 ± 0.07 0.429
  4wks 0.04 ± 0.05* 0.04 ± 0.04* 0.04 ± 0.04* 0.889
  12wks 0.05 ± 0.04* 0.05 ± 0.05* 0.04 ± 0.03* 0.171
Table 3. Changes in Corneal Aberrations between Preoperative and 4 and 12 Weeks after Cataract Surgery. 
Data are presented as mean ± standard deviation. P-value indicates the statistical analysis among the three 
groups. *Indicates a statistically significant result when compared with preoperative value.
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treating MGD following cataract surgery. The relationship between cataract surgery and MGD has been exam-
ined in many studies, with MGD identified as a key cause of DED following cataract surgery8,26,27. Studies have 
shown that meibomian gland function deterioration has persisted for 3 months postoperatively, suggesting that 
MGD may lead to persistent dry eye symptoms26. In fact, a recent study of our group revealed meibomian gland 
orifice obstruction and meibomian gland dropout to be associated with persistent dry eye symptoms after cataract 
surgery1. We report here that diquafosol can improve MGD-related parameters more than sodium hyaluronate in 
DED patients after cataract surgery. These results suggest that diquafosol may be helpful in the treatment of MGD 
and may further have protective effects against persistent DED following cataract surgery.
Interestingly, TBUT was significantly improved at 3 months after surgery only in group 1, although TBUT 
at 1 month after surgery was improved in both groups 1 and 2. This difference may be caused due to long-term 
preservative usage in group 2. Similarly, the reduction in OSDI scores was comparable between group 1 and 
group 2 at 1 month postoperatively; however, it decreased further in group 1 at 3 months after surgery, despite 
not reaching a statistically significant value with groups 1 and 2 at 3 months postoperatively. Chronic preservative 
usage seems to decrease the efficacy of the eye drops in dry eye treatment. It might have caused further reduction 
of MGD stage in group 1 than in group 2 at 3 months after phacoemulsification; however, MGD stage reduced in 
both groups 1 and 2 at 1 month postoperatively.
Regarding corneal HOAs after cataract surgery, we found that corneal HOAs improved after cataract surgery 
across all 3 groups and there were no significant differences among the 3 groups. We hypothesize that because 
subjects in the present study had preoperative DED, their use of medication after surgery led to HOA improve-
ments in all groups. However, previous studies have shown that diquafosol simply maintained postoperative 
HOAs, while artificial tears did not prevent deterioration of HOAs2,5,19. Another study revealed that diquafo-
sol treatment reduced HOAs as well as corneal staining scores in aqueous-deficient dry eye, suggesting that 
improvement in superficial punctate keratopathy resulted in HOA reductions28. Similarly, we also hypothesize 
that improvements in corneal staining scores elicited improvements in HOAs in the present study.
Refinement of eye drop ingredients is necessary for improved clinical outcomes. Preservatives in eye drops have 
previously been implicated in epithelial damage29. Preservative-free medications have previously been shown to lead 
to greater improvements in OSDI, TBUT, corneal staining scores, and Schirmer test scores in patients with DED 
after phacoemulsification than preservative-containing medications16. Furthermore, glaucoma patients who used 
preservative-free prostaglandin/timolol fixed combinations manifested better results in not only dry eye parameters, 
Figure 2. Changes to corneal higher-order aberrations (HOAs) during the treatment period in patients with 
pre-existing dry eye disease (DED). The mean change to total corneal HOAs (a), spherical aberrations (b), coma 
(c), trefoil (d), and secondary astigmatisms (e) were depicted. Data are presented as mean values ± standard 
error of the mean (SEM). P-values are presented next to all graphs for each study period, indicating the results 
of statistical analyses among the 3 groups for that period using analysis of variance; ¶P-value indicates the overall 
analysis throughout the study period by generalized estimating equation; †indicates a statistically significant 
difference between groups 1 and 2 per post hoc analysis; ‡indicates a statistically significant difference between 
groups 1 and 3 per post hoc analysis; §indicates a statistically significant difference between groups 2 and 3 per 
post hoc analysis.
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but also meibomian gland features than did those who used preserved prostaglandin/timolol fixed combinations30. As 
outlined here, preservative-free diquafosol led to better dry eye and MGD parameters than preservative-containing 
diquafosol at 3 months after phacoemulsification in the present study. However, the preservative-free diquafosol group 
showed results comparable to the preserved diquafosol group at 1 month after surgery. There are two potential rea-
sons for this. First, preservatives may not lead to negative clinical effects in the relatively limited, 1-month timespan 
assessed here. Second, postoperative medications containing preservatives were used for 1 month following surgery in 
all groups, with potential significant differences not emerging until 3 months.
While the present study offers some intriguing results, it has some limitations that are worth discussing. First, 
this study was not designed as a blind clinical trial, so there is a risk of bias even though the researcher has evalu-
ated it as fair as possible. Second, the sample size of the present study was relatively small and our study follow-up 
period of only 3 months was relatively short. However, it is important to note that most changes to the ocular 
surface following phacoemulsification resolve within a few months31,32. Larger sample sizes and more long-term 
double-blind studies may allow further validation of the present study’s results. Third, we have some concerns 
about the confounding effect of postoperative use of topical antibiotics and steroid eye drops in the present study’s 
results. For example, anti-inflammatory medications are especially associated with dry eye symptoms and may 
improve MGD parameters to some degree5,33. Furthermore, the postoperative anti-inflammatory eye drops used 
in this study contained preservatives. However, all patients in the 3 groups used postoperative antibiotics and 
steroid medications in the same way; therefore, the differences between the 3 groups in this study are thought to 
be mainly generated by the eye drops for dry eye.
Despite the limitations, the current study is valuable because it is the first to report the efficacy of 
preservative-free diquafosol ophthalmic solution in DED patients. Moreover, we comparatively demonstrated 
clinical outcomes associated with sodium hyaluronate and diquafosol with and without preservatives in patients 
with DED who underwent phacoemulsification using a randomized clinical trial design. The present study’s find-
ings provide evidence for a novel treatment strategy involving the use of preservative-free diquafosol for the 
management of eye health and DED following cataract surgery.
In conclusion, the present study revealed that a 3% diquafosol ophthalmic solution was more effective than 
a sodium hyaluronate ophthalmic solution in managing DED after cataract surgery, whether it contained a pre-
servative or not. Furthermore, although preservative-containing diquafosol led to clinical outcomes comparable 
with preservative-free diquafosol at 1 month after surgery, use of preservative-free diquafosol resulted in better 
outcomes at 3 months after surgery, suggesting that preservative use may be detrimental to DED treatment.
Patients and Methods
Subjects. This study involved a prospective randomized controlled clinical trial design and was approved by 
the Institutional Review Board of Yonsei University College of Medicine (Seoul, South Korea; IRB No. 4-2017-
0601; Date of approval: 15 August 2017) and was registered at ClinicalTrials.gov (NCT03640351, Date of regis-
tration: 21 August 2018). All study procedures followed the tenets of the Declaration of Helsinki, and written 
informed consent was obtained from all participants. The study used a prospective randomized design and was 
conducted according to the original protocol (full protocol available on request).
We enrolled patients with pre-existing DED scheduled to undergo cataract surgery. We defined DED with minor 
modifications based on the standards set in the Tear Film and Ocular Surface Society Dry Eye Workshop II Diagnostic 
Methodology report34. We diagnosed DED when OSDI score was 13 or more and one of the following two condi-
tions was satisfied: 1) TBUT less than 10 seconds or 2) ocular surface staining showing >5 corneal spots. Participant 
exclusion criteria included an age less than 20 years, previous use of tetracycline or eye drops except artificial tears 
within 3 months prior to cataract surgery, the presence of any severe ocular surface disease and/or corneal epithe-
lial pathologies (except DED), a history of previous ocular surgery or trauma, ocular comorbidities, such as glau-
coma, uveitis, and cystoid macular oedema. All patients underwent cataract extraction with phacoemulsification and 
intraocular lens implantation at Yonsei University College of Medicine, Seoul, Republic of Korea, between August 
2017 and September 2018. Participants were randomly assigned into the preservative-free diquafosol group (group 1), 
the preservative-containing diquafosol group (group 2), or the hyaluronate group (group 3) via a simple, unrestricted 
randomization method by the controller (Supplementary Fig. S1). Group 1 used preservative-free 3% diquafosol tet-
rasodium ophthalmic solution (Diquas-S; Santen Pharmaceutical Co, Ltd, Osaka, Japan) 6 times a day, while group 2 
used 3% diquafosol tetrasodium ophthalmic solution (Diquas; Santen Pharmaceutical Co, Ltd) which contains chlor-
hexidine as preservative, 6 times a day, and group 3 used preservative-free 0.15% sodium hyaluronate ophthalmic 
solution (New Hyaluni 0.15%; Taejoon, Seoul, Korea) 6 times a day. All 3 groups used eye drops from postoperative day 
1 to 12 weeks after surgery. The calculated total sample size was 111 when we set effect size 0.3, power 0.80, and α 0.05; 
therefore, we enrolled 50 subjects in each group considering follow up loss. Right or left eye data were randomly chosen 
using randomization tables, regardless of ocular dominance, refraction, or presence of aberrations.
Preoperative and postoperative assessments. All subjects underwent dry eye and MGD examinations 
before and 1 and 3 months after cataract surgery. The subjects did not use any eyedrops prior to 2 hours of exam-
ination. These examination parameters included TBUT, type I Schirmer test scores, Oxford staining scores, and 
OSDI scores. MGD parameters consisted of LLT, lid margin abnormalities, meibum quality, meibum expressi-
bility, MGD stage, and meibomian gland dropout. We evaluated LLT, meibomian gland dropout, TBUT, Oxford 
staining scores, lid margin abnormality, meibum quality, meibum expressibility, MGD stage, OSDI scores, and 
Schirmer test scores in order. Corneal aberrations in all subjects were measured via iTrace (Tracey Technology, 
Houston, TX, USA), as previously described35.
TBUT was evaluated by placing a single fluorescein strip (Haag-Streit, Koeniz, Switzerland) over the inferior 
meniscus. The mean of 3 evaluation attempts was used for analysis. The Schirmer test was performed without topical 
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anaesthesia using a standard paper strip (Eagle Vision, Memphis, TN) for 5 minutes. The OSDI Questionnaire, devel-
oped by the Outcomes Research Group at Allergan (Irvine, CA), was used to assess dry eye symptoms. LLT was meas-
ured with the LipiView 2 system (Tear-Science, Morrisville, NY). Meibomian gland dropout was graded between 0 and 
4 from a low lid meibomian gland image obtained with the LipiView 2 system36. Lid margin abnormalities were graded 
from 0 to 4 according to the following 4 factors: vascular engorgement, plugged meibomian gland orifice, anterior or 
posterior displacement of the mucocutaneous junction, and irregularity of the lid margin1,37,38. The meibum quality of 
8 glands in the centre of the lower lid was scored from 0 to 241,38. Meibum expressibility was assessed using firm digital 
pressure over 5 lower lid glands and calculated semi-quantitatively, as previously described1,39. The MGD stage was 
determined by evaluating clinical symptoms, fluorescein staining of the cornea and conjunctiva, lid margin abnormal-
ities, expressibility, and any altered secretion by a single clinician (I.J.) as previously described1,40.
Surgical technique. All cataract surgeries were performed by one surgeon (T.K.). Phacoemulsification and 
cataract extractions were performed using the Centurion Vision System (Alcon Laboratories, Inc., Lake Forest, 
CA, USA) after a 2.8-mm clear corneal incision was made under topical anaesthesia. All patients underwent 
intraocular lens implantation in the capsular bag. Patients were instructed to instil one drop each of topical 
0.5% levofloxacin (Cravit, Santen Pharmaceutical, Osaka, Japan; preservative-free) and 0.1% fluorometholone 
(Ocumetholone, Samil Pharmaceutical, Seoul, Korea; containing benzalkonium chloride as preservative) 4 times 
a day, and 0.1% bromfenac sodium (Bronuck, Taejoon, Seoul, Korea; containing benzalkonium chloride as pre-
servative) 2 times a day for 4 weeks following surgery.
Statistical analyses. Data are expressed as mean values ± standard deviation or standard error as described 
in the legend of the figures and tables. Analyses of variance, followed by Tukey’s multiple comparison test or the 
Kruskal-Wallis test with Bonferroni post hoc analysis, were performed, as appropriate. Differences were con-
sidered to be statistically significant at P < 0.05. A generalized estimating equation with Bonferroni post hoc 
analysis was used for repeated measurements to compare overall differences throughout the study period among 
the 3 groups. For Bonferroni post hoc analyses, P < 0.0167 was considered significant. Statistical analyses were 
performed using SPSS statistics software (version 23; IBM Corporation, Armonk, NY).
Data Availability
The datasets generated during and/or analysed during the current study are available from the corresponding 
author on reasonable request.
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